References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2017-2-80-87

mrj-760

Research Article

ОБЗОРЫ

REVIEWS

Лечение остеоартрита: фокус на нимесулид

Treatment of osteoarthritis: A focus on nimesulide

Имаметдинова

Г. Р.

Imametdinova

G. R.

kafedraRheum@yandex.ru

Чичасова

Н. В.

Chichasova

N. V.

kafedraRheum@yandex.ru

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России, МоскваРоссияI.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, MoscowRussian Federation

2017

25042017

1128087

2017

Имаметдинова Г.Р., Чичасова Н.В.

Imametdinova G.R., Chichasova N.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/760

Широкое распространение остеоартрита (ОА), высокая инвалидизация пациентов определяют не только медицинскую, но и социально-экономическую значимость этого заболевания. В последние годы отмечена тенденция к увеличению частоты ОА. По современным представлениям, воспаление имеет ведущее значение в формировании хронической боли при ОА, что требует проведения адекватной противовоспалительной терапии. Приведены данные о многообразных механизмах действия нестероидного противовоспалительного препарата (НПВП) нимесулида, а также результаты клинических исследований и метаанализов, подтверждающие его эффективность и хорошую переносимость. В нескольких клинических исследованиях, включавших 22 938 больных ОА, показано, что общая частота нежелательных реакций (НР) при использовании нимесулида составила 8,2%. Приводятся данные об эффективности и хорошей переносимости локальных форм НПВП, а также комбинированных препаратов глюкозамина сульфата и хондроитина сульфата, использование которых совместно с пероральными лекарственными средствами позволяет увеличить эффективность лечения без повышения риска развития НР.

Widespread osteoarthritis (OA) and high related disability rates determine not only the medical, but also socioeconomic significance of this disease. In recent years there has been a tendency to increase the incidence of OA. According to the current concepts, inflammation plays a leading role in the development of chronic pain in OA, which requires adequate anti-inflammatory therapy. There are data on the diverse mechanisms of action of the nonsteroidal anti-inflammatory drug (NSAID) nimesulide and results from clinical trials and metaanalyses, which confirm its efficacy and good tolerability. Several clinical trials covering 22,938 patients with OA have indicated that the overall frequency of adverse reactions (AR) from nimesulide is 8.2%. There is evidence on the efficacy and good tolerability of topical NSAIDs, as well as combination drugs containing glucosamine sulfate and chondroitin sulfate, the use of which together with oral drugs enhances the efficiency of treatment without increasing the risk of ARs.

остеоартритнестероидные противовоспалительные препаратынимесулидлокальные формы нестероидных противовоспалительных препаратовпрепараты глюкозамина сульфата и хандроитина сульфата

osteoarthritisnonsteroidal inflammatory drugsnimesulidetopical nonsteroidal inflammatory drugsdrugs containing glucosamine sulfate and chondroitin sulfate

References1

Наумов АВ, Шамуилова ММ. Остеоартроз в современной клинической практике: анализ факторов и рекомендации. Терапевт. 2009;(10):5-33. [Naumov AV, фShamuilova MM. Osteoarthritis in modern clinical practice: analysis of the factors and recommendations. Terapevt. 2009;(10):5-33 (in Russ.)].

Kraus VB, Blanco FJ, Englund M, et al. Call for Standardized Definitions of Osteoarthritis and Risk Stratification for Clinical Trials and Clinical Use. Osteoarthritis Cartilage. 2015 Aug;23(8):1233-41. doi: 10.1016/j.joca.2015.03.036. Epub 2015 Apr 9.

WHO Scientific Group. The burden of musculoskeletal conditions at the start of the new millennium. World Health Organ Tech Rep Ser. 2003;919:i-x, 1-218, back cover.

Rabenda V, Manette C, Lemmens R, et al. Direct and indirect costs attributable to osteoarthritis in active subjects. J Rheumatol. 2006 Jun;33(6):1152-8.

Gobelet C, Luthi F, Al-Khodairy AT, Chamberlain MA. Work in inflammatory and degenerative joint diseases. Disabil Rehabil. 2007 Sep 15;29(17):1331-9.

Cooper C, Arden NK. Excess mortality in osteoarthritis. BMJ. 2011 Mar 8;342:d1407. doi: 10.1136/bmj.d1407.

Насонов ЕЛ, Яхно НН, Каратеев АЕ и др. Общие принципы лечения скелетно-мышечной боли: междисциплинарный консенсус. Научно-практическая ревматология. 2016;(54)3:247-65. [Nasonov EL, Yakhno NN, Karateev AE, et al. General princihles of treatment for musculoskeletal pain: interdisciplinary consensus. Nauchno-prarticheskaya revmatologiya = Rheumatology Science and Practice. 2016;54(3):247-65. (In Russ.)]. doi:10.14412/1995-4484-2016-247-265

Autokarala I, Kwoh CK, Guermazi A, et al. Synovitis in knee osteoarthritis: a precursor of disease? Ann Rheum Dis. 2016 Feb;75(2): 390-5. doi: 10.1136/annrheumdis-2014- 205894. Epub 2014 Dec 8

Haugen IK, Boyesen P, SlatowskyChritensen B, et al. Comparison of features by MRI and radiographs of the interphalangeal finger joints in patients with hand osteoarthritis. Ann Rheum Dis. 2012 Mar;71(3):345-50. doi: 10.1136/ annrheumdis-2011-200028. Epub 2011 Oct 11

Glimm AM, Werner SG, Burmester GR, et al. Analysis of distribution and severity of inflammation in patients with osteoarthritis compared to rheumatoid arthritis by IGG-enhanced fluorescence optical imaging and musculosckeletal ulnrasound: a pilot atudy. Ann Rheum Dis. 2016 Mar;75(3):566-70. doi: 10.1136/annrheumdis-2015-207345. Epub 2015 Aug 26

Pelletier JP, Martel- Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum. 2001 Jun;44(6):1237-47. doi: 10.1002/1529-0131 (200106)44:63.0.CO;2-F

Schaible H. Mechanisms of chronic pain in osteoarthritis. Curr Rheumatol Rep. 2012;14(6): 549-56. doi: 10.1007/s11926-012-0279-x

Pincus T. Clinical evidence for osteoarthritis as an inflammatory disease. Curr Rheumatol Rep. 2001 Dec;3(6):524-34.

Dawson J, Linsell L, Zondervan K, et al. Impact of persistent hip or knee pain overall health status in erderly People: a longitudinal population study. Arthritis Rheum. 2005 Jun 15;53(3):368-74.

Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63. doi: 10.1016/j.semarthrit.2014.05.014. Epub 2014 May 14.

Zang W, Nuki G, Moscowitz RW, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010 Apr;18(4):476-99. doi: 10.1016/j.joca. 2010.01.013. Epub 2010 Feb 11.

FDA. Drug Safety Communication 13 January 2011: Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver failure. http://www.fda.gov/ Drugs/ DrugSafety/ucm239821.htm

Rahme E, Bakcun A, Nedjar H, et al. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among erderly in Quebec, Canada. Am J Gastroenterol. 2008 Apr;103(4):872-82. doi: 10.1111/j. 1572-0241.2008.01811.x. Epub 2008 Mar 26.

Curhan GC, Knight EL, Rosner B, et al. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med. 2004 Jul 26;164(14):1519-24.

Curhan GC, Willet WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med. 2002 Oct 28;162(19):2204-8.

Forman JP, Rimm EB, Curhan GC. Frequency of analgesic use and risk of hypertension among men. Arch Intern Med. 2007 Feb 26;167(4):394-9.

Roberts E, Nunes VD, Buckner S, Latchem S. Paracetamol: not as the safe as we though? A systematic literature review of observational studies. Ann Rheum Dis. 2016 Mar;75(3):552-9. doi: 10.1136/annrheumdis- 2014-206914

Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;(1):4-23. [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal antiinflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya= Modern Rheumatology Journal. 2015;(1):4-23. (in Russ.)]. doi: http://dx.doi.org/10.14412/ 1996-7012-2015-1-4-23

Rainsford KD; Members of the Consensus Report Group on Nimesulide. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin. 2006 Jun; 22(6):1161-70.

Bennett A. Nimesulide a well established cyclooxygenase-2 inhibitor with many other pharmacological properties relevant to inflammatory diseases. In: Vein JR, Botting RM, editors. Therapeutic Roles of Selective COX-2 Inhibitors. William Harvey Press. P. 524-40.

Bunczak-Reeh MA, Hargreaves KM. Effect on inflammation on the delivery of drugs to dental pulp. J Endod. 1998 Dec; 24(12):822-5.

Насонов ЕЛ. Эффективность и переносимость нестероидного противовоспалительного препарата. Нимесулид: новые данные. Русский медицинский журнал. 2001;(15):6-8. [NasonovEL. Efficacy and tolerability of nonsteroidal anti-inflammatory drug. Nimesulide: new data. Russkii Meditsinskii Zhurnal. 2001;(15):6-8. (In Russ.)].

Singla AK, Chawla M, Singh A. Nimesulid: some pharmaceutical and pharmacological aspects – an update. J Pharm Pharmacol. 2000 May;52(5):467-86.

Rainsford KD. Nimesulide: overview of properties and applications. Drugs Today. 2001;37(Suppl. B):3-7.

Garcia-Nieto B, Perez C, Checa A, Gago F. Molecular model of the interaction between nimesulide and human cyclooxigenase-2. Rheumatol. 1999;38(Suppl.):14-8.

Famey JP. In vitro and in vivo pharmacological evidence of selective cyclooxigenase-2 inhibition de nimesulide: an overview. Inflamm Res. 1997 Nov;46(11):437-46.

Benett A, Villa G. Nimesulide: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Expert Opin Pharmacother. 2000 Jan;1(2):277-86.

Cullen L, Kelly L, Connor SO, Fitzgerald DJ. Selective cvclooxvgenase-2 inhibition bv nimesulide in man. J Pharmacol Exp Ther. 1998 Nov;287(2):578-82.

Kerola M, Vuolteenaho K, Kosonen O, et al. Effects of nimesulide, acetylsalicylic acid, ibuprofen and nabumetone on cyclooxygenase-1 and cyclooxygenase-2- mediated prostanoid production in healthy volunteers ex vivo. Basic Clin Pharmacol Toxicol. 2009 Jan;104(1):17-21. doi: 10.1111/j.1742-7843.2008.00332.x.

Suleyman H, Cadirci E, Albayrak A, Halici Z. Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatorv drug. Curr Med Chem. 2008; 15(3):278-83.

Mikherjee P, Rachita C, Aisen PS, Pasineti GM. Nonsteroidal anti-inflammatory drugs protect against chondrocyte apoptotic death. Clin Exp Rheumatol. 2001;19 (1 Suppl 22):S7-11.

Pelletier JP, Martel-Pelletier J. Effects of nimesulide and naproxen on the degranulation and metalloprotease synthesis of human osteoarthritic cartilage. Drugs. 1993;46 Suppl 1:34-9.

Facino RM, Carini V, Aldini G. Antioxidant activity of nimesulide and its main metabolites. Drugs. 1993;46 Suppl 1:15-21.

Bianchi M, Broggini M, Balzarini P, et al. Effects of nimesulide on pain and on synovial fluid concentrations of substance P, interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib. Int J Clin Pract. 2007 Aug;61(8):1270-7. Epub 2007 Jun 22.

Shan AA, Murray FE, Fitzgerald DJ. The in vivo assessment of nimesulide cyclooxygenase selectivity. Rheumatol. 1999;38(Suppl.):19-23.

Bennet A. Clinical importance of the multifactorial actions of nimesulide. Drugs Today. 2001;37(suppl.B):9-14.

Tassorelli C, Greco R, Sandrini G, Nappi G. Central components of the analgesic/antihyperalgesic effect of nimesulide: studies in animal models of pain and hyperalgesia. Drugs. 2003;63 Suppl 1:9-22.

Bianchi M, Martucci C, Ferrario P, et al. Increased Tumor Necrosis Factor and Prostaglandin E2 Concentrations in the Cerebrospinal Fluid of Rats with Inflammatory Hyperalgesia: The Effects of Analgesic Drugs. Anesth Analg. 2007 Apr; 104(4):949-54.

Pochobradsky MG, Mele G, Beretta A. Postmarketing survey of nimesulide in the chort-term treatment of osteoarthritis. Drugs Exp Clin Res. 1991;17(3):197-204.

Каратеев АЕ. Гастродуоденальная безопасность селективных ингибиторов циклооксигеназы-2: проверка практикой. Терапевтический архив. 2005;(5):69-72. [Karateev AE. Gastroduodenal safety of selective inhibitors of cyclooxygenase-2: the test of practice. Terapevticheskii arkhiv. 2005;(5):69-72. (In Russ.)].

Каратеев АЕ, Алексеева Л.И, Братыгина ЕА, Аширова ТБ. Оценка частоты развития побочных эффектов при длительном применении нимесулида в реальной клинической практике. Русский медицинский журнал. 2009;17(21):1466-72. [Karataev AE., Alekseeva LI, Batygina EA, Ashirova TB. Assessment of the incidence of side effects with prolonged use of nimesulide in real clinical practice. Russkii Meditsinskii Zhurnal. 2009;17(21):1466-72. (In Russ.)].

Porto A, Almeida H, Cunha MJ, Macciocchi A. Double-blind evaluation by endoscopy the tolerability of nimesulide and diclofenac on gastric mucosa in osteoarthritis patients. Eur J Rheumatol Inflamm. 1994; 14(4):33-8.

Bradbury F. How important is the role of the physician in the correct use of a drug? An observational cohort study in general practice. Int J Clin Pract Suppl. 2004 Oct;(144):27-32.

Bjarnason I, Thjodleisson B. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract. Rheumatology (Oxford). 1999 May;38 Suppl 1:24-32.

Fusetti G, Magni E, Armandola MC. Tolerability of nimesulide. Epidemiological data. Drugs. 1993;46(suppl.1):277-80.

Mele G, Memeo A, Mellesi L, Gatti F. Postmarketing surveillance on nimesulide in the treatment of 8354 patients over 60 years old affected with acute and chronic musculoskeletal diseases. Arch. Med. Intern. 1992;44: 213-21.

Mattia C, Ciarcia S, Muchindo A, Coluzzi F. Nimesulide: 25 years later. Minerva Med. 2010 Aug;101(4):285-93.

Conforti A, Leone R, Moretti U, et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf. 2001;24(14):1081-90.

Laporte J, Ibanez L, Vidal X, Leone R. Upper gastrointestinal bleeding associated with the use of NSAIDS: newer versus older agents. Drug Saf. 2004;27(6):411-20.

Каратеев АЕ, Насонова ВА. Развитие и рецидивирование язв желудка и двенадцатиперстной кишки у больных, принимающих нестероидные противовоспалительные препараты: влияние стандартных факторов риска. Терапевтический архив. 2008;(5):62-6. [Karateev AE, Nasonova VA. The development and recurrence of gastric ulcers and duodenal ulcers in patients taking nonsteroidal anti-inflammatory drugs: effects of standard risk factors. Terapevticheskii arkhiv. 2008;(5):62-6. (In Russ.)].

Helin-Salmivaara A, Virtanen A, Veslainen R, et al. NSAID use and the risk of hospitalisation for first myocardial infarction in the general population: a national casecontrol study from Finland. Eur Heart J. 2006 Jul;27(14):1657-63. Epub 2006 May 26.

Чичасова НВ, Имаметдинова ГР, Насонов ЕЛ. Нимесулид в лечении хронических заболеваний суставов. Лечащий врач. 2008;(4):75-8. [Chichasova NV, Imametdinova GR, Nasonov EL. Nimesulide in the treatment of chronic diseases of the joints. Lechashchii vrach. 2008;(4):75-8. (In Russ.)].

Низовцева ОА. Применение нимесулида (селективного ингибитора ЦОГ-2) при остеоартрозе в сочетании с артериальной гипертензией. Трудный пациент. 2008;6(4):31-4. [Nizovtseva OA. Use of nimesulide (selective COX-2 inhibitor) in osteoarthritis in combination with hypertension. Trudnyi patsient. 2008;6(4):31-4. (In Russ.)].

Каратеев АЕ, Насонова ВА. НПВП-ассоциированная гепатопатия: проблема нимесулида. Научно-практическая ревматология. 2003;41(4):87-91. [Karateev AE, Nasonova VA. NSAID-associated hepatopathy: the problem of nimesulide. Nauchnoprarticheskaya revmatologiya = Rheumatology Science and Practice. 2003;41(4):87-91. (In Russ.)]. doi: 10.14412/1995-4484-2003-1342

Boesterli U. Nimesulide and hepatic adverse affects: roles of reactive metabolites and host factors. Int J Clin Pract Suppl. 2002 Jul;(128):30-6.

Boesterli U. Mechanisms of NSAIDinduced hepatotoxity: focus on nimesulide. Drug Saf. 2002;25(9):633-48.

Traversa G, Bianchi C, Da Cas R, et al. Cohort study of hepartotoxity associated with nimesulide and other non-steroidal antiinflammatory drugs. BMJ. 2003 Jul 5;327 (7405):18-22.

Каратеев АЕ, Барскова ВГ. Безопасность нимесулида: эмоции или взвешенная оценка? Consilium Medicum. 2007;(9):60-4. [Karataev AE, Barskova VG. Safety of nimesulide: emotions or weighted score? Consilium Medicum. 2007;(9):60-4. (In Russ.)].

Leone R, Conforti A, Chiotto E, et al. Nimesulide and renal impairment. Eur J Clin Pharmacol. 1999 Apr;55(2):151-4.

Warrington SJ, Ravic M, Dawnay A. Renal and general tolerability of repeated doses of nimesulide in normal subjects. Drugs. 1993;46(Suppl. 1):263-9.

Насонов ЕЛ, Каратеев АЕ. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. Русский медицинский журнал. 2006;14 (25):1769-77. [Nasonov EL, Karateev AE. The use of nonsteroidal antiinflammatory drugs. Clinical guidelines. Russkii Meditsinskii Zhurnal. 2006;14 (25):1769-77. (In Russ.)].

Senna GE, Passalacqua G, Dama A, et al. Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs. Eur Ann Allergy Clin Immunol. 2003 Dec;35(10):393-6.

Kullich WC, Niksic F, Clean G. Effect of nimesulide on metalloproteinases and matrix degradation in osteoarthritis: A pilot clinical study. Int J Clin Pract Suppl. 2002 Jul; (128):24-9.

Lü cker P, Pawlowski C, Friedrich I, et al. Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee. Eur J Rheumatol Inflamm. 1994;14(2):29-38.

Kriegel W, Korff K, Ehrlich J, et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract. 2001 Oct;55(8):510-4.

Балабанова РМ, Гришаева ТП, Степанец ОВ. Эффективность и переносимость нимулида у больных ревматическими заболеваниями. Научно-практическая ревматология. 2004;42(1):48-50. [Balabanova RM, Grishaeva TP, Stepanets OV. Efficacy and tolerability of nimulid in patients with rheumatic diseases. Nauchno-prarticheskaya revmatologiya = Rheumatology Science and Practice. 2004;42(1):48-50. (In Russ.)]. doi: 10.14412/1995-4484-2004-1383

Коган КМ, Золотарева ГД, Бернштейн ИЛ и др. Практический опыт применения препаратов нимулид и КОНДРОнова® окружными специалиста- ми и врачами-ревматологами г. Москвы. Научно-практическая ревматология. 2005;43(4):58-61. [Kogan KM, Zolotareva GD, Bernshtein IL, et al. Practical expirience of nimulid and CONDROnova® administration by District specialists and rheumatologists of Moscow. Nauchno-prarticheskaya revmatologiya = Rheumatology Science and Practice. 2005; 43(4):58-61. (In Russ.)].

Маслова ЕС, Злобина ТИ, Тупицына ГВ и др. Нимулид – селективный нестероид- ный противовоспалительный препарат в лечении гонартроза у пожилых. http://www.coralmed-corp.ru [Maslova EU, Zlobina TI, Tupitsyna GV, et al. Nimulid – selective non-steroidal anti-inflammatory drug in the treatment of osteoarthritis in the elderly. http://www.coralmed-corp.ru (In Russ.)].

Якушин СС, Лыгина ЕВ. Эффективность применения нимулида – селективного ингибитора ЦОГ-2 у больных остео- артрозом. Тезисы II Всероссийской конференции ревматологов «Социальные аспекты ревматических заболеваний». Воронеж, 24-26 мая 2006 г. Научно-практическая ревматология. 2006;( 2s):125. [Yakushin SS, Lygina EV. The efficacy of nimulid – selective COX-2 inhibitor in patients with osteoarthritis. Abstracts of the II All-Russian conference for rheumatologists «Social aspects of reminiscences diseases». Voronezh, May 24-26, 2006. Nauchno-prarticheskaya revmatologiya = Rheumatology Science and Practice. 2006; (2s):125. (In Russ.)].

Лыгина ЕВ. Эффективность и безопасность применения нимулида у больных остеоартрозом в сочетании с гипертонической болезнью. Российский медико- биологический вестник им. академика И.П. Павлова. 2006;(1):44-50. [Lygina EV. The efficacy and safety of the use of nimulid in patients with osteoarthritis in combination with hypertension. Rossiiskii mediko-biologicheskii vestnik im. akademika I.P. Pavlova. 2006;(1):44-50. (In Russ.)].

Massey T, Derry S, Moore R, McQuay H. Topical NSAIDs for acute pain in adults. Cochrane Database Syst Rev. 2010 Jun 16; (6):CD007402. doi: 10.1002/14651858. CD007402.pub2.

Sengupta S, Velpandian T, Kabir SR, Gupta SK. Analgesic efficacy and pharmacokinetics of topical nimesulide gel in healthy human volunteers: double-blind comparison with piroxicam, diclofenac and placebo. Eur J Clin Pharmacol. 1998 Sep;54(7):541-7.

Erdogan F, Ergü n H, Gocay NS, et al. The diffusion of nimesulide gel into synovial fluid: a comparison between administration routes. Int J Clin Pharmacol Ther. 2006 Jun; 44(6):270-5.

Ergü n H, Kulcu D, Kutlay S. et al. Efficacy and safety of topical nimesulide in the treatment of knee osteoarthritis. J Clin Rheumatol. 2007 Oct;13(5):251-5.

Mako S, Stampf G. Transdermal therapeutic systems. Acta Pharm Hung. 2001 Oct; 71(3):293-9.

Berti JJ, Lipsky JJ. Transcutaneous drug delivery: a practical review. Mayo Clin Proc. 1995 Jun;70(6):581-6.

The authors declare that there are no conflicts of interest present.